Gilead Sciences

News

Merck halts more trials of HIV candidate islatravir

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy.

News

Hepatitis Virus - 3d rendered illustration

Gilead files first hepatitis delta therapy with FDA

Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA.

News

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Gilead Sciences' Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a reg

News

Gilead tags Merck for first-line triple negative breast canc...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

News

Kite claims a first for CAR-T Tecartus in adult leukaemia

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an

News

Galapagos' long-serving CEO Onno van de Stolpe to retire

After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership.

Merck halts more trials of HIV candidate islatravir

Gilead files first hepatitis delta therapy with FDA

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Gilead tags Merck for first-line triple negative breast canc...

Kite claims a first for CAR-T Tecartus in adult leukaemia

Galapagos' long-serving CEO Onno van de Stolpe to retire

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Gilead Sciences

Editor's Picks